
Diego A. Díaz García/X
Apr 8, 2025, 02:38
Diego A. Díaz García: Active surveillance is effective in patients with stage I NSGCT
Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:
“Active surveillance is effective in patients with stage I NSGCT.
In a 457-patient cohort (median FU: 65.3 months), 20% relapsed, but >90% were cured with salvage therapy.
20-year OS: 98.25%.
VI was the strongest predictor of recurrence.”
Authors: Jorge Martínez-Cedillo et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 12:02
Apr 15, 2025, 11:54
Apr 15, 2025, 11:52
Apr 15, 2025, 11:46
Apr 15, 2025, 11:30